Supervised learning with word embeddings derived from PubMed captures latent knowledge about protein kinases and cancer

Author:

Ravanmehr Vida1,Blau Hannah1,Cappelletti Luca2,Fontana Tommaso2,Carmody Leigh1,Coleman Ben13,George Joshy1ORCID,Reese Justin4,Joachimiak Marcin4,Bocci Giovanni5,Hansen Peter1,Bult Carol6ORCID,Rueter Jens6,Casiraghi Elena2,Valentini Giorgio2ORCID,Mungall Christopher4ORCID,Oprea Tudor I5ORCID,Robinson Peter N17ORCID

Affiliation:

1. The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA

2. AnacletoLab, Dipartimento di Informatica, Università degli Studi di Milano, Italy

3. University of Connecticut Health Center, Department of Genetics and Genome Sciences, Farmington, CT 06030, USA

4. Division of Environmental Genomics and Systems Biology, Lawrence Berkeley National Laboratory, Berkeley, CA 94710, USA

5. Department of Internal Medicine and UNM Comprehensive Cancer Center, UNM School of, Medicine, Albuquerque, NM 87102, USA

6. The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME 04609, USA

7. Institute for Systems Genomics, University of Connecticut, Farmington, CT 06032, USA

Abstract

Abstract Inhibiting protein kinases (PKs) that cause cancers has been an important topic in cancer therapy for years. So far, almost 8% of >530 PKs have been targeted by FDA-approved medications, and around 150 protein kinase inhibitors (PKIs) have been tested in clinical trials. We present an approach based on natural language processing and machine learning to investigate the relations between PKs and cancers, predicting PKs whose inhibition would be efficacious to treat a certain cancer. Our approach represents PKs and cancers as semantically meaningful 100-dimensional vectors based on word and concept neighborhoods in PubMed abstracts. We use information about phase I-IV trials in ClinicalTrials.gov to construct a training set for random forest classification. Our results with historical data show that associations between PKs and specific cancers can be predicted years in advance with good accuracy. Our tool can be used to predict the relevance of inhibiting PKs for specific cancers and to support the design of well-focused clinical trials to discover novel PKIs for cancer therapy.

Funder

NIH

NCI

DOE

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3